This clinical trial is focused on studying the effectiveness and safety of a new treatment for people with allergic rhinitis or rhinoconjunctivitis, which are conditions that cause symptoms like sneezing, runny nose, and itchy eyes. These conditions can occur with or without mild to moderate asthma, a condition that affects breathing. The treatment being tested is a vaccine made from a mixture of modified allergen extracts from six types of grasses and olive pollen, known by the code name MG01_T517. The purpose of the study is to evaluate how well this vaccine works when given as an injection under the skin compared to a placebo.
Participants in the study will receive injections of either the vaccine or a placebo over a period of up to 12 months. The study will monitor the participants’ symptoms and any medication they use during the grass and olive tree pollen season, which typically occurs in April, May, and June. The study will also look at the number of days participants are free from symptoms and medication, any worsening of asthma symptoms, and overall quality of life related to rhinitis. Additionally, the study will assess the safety of the vaccine by tracking any side effects or reactions at the injection site.
The trial aims to provide valuable information on whether the vaccine can help reduce symptoms and improve the quality of life for people with allergies to grasses and olive trees. By comparing the vaccine to a placebo, researchers hope to determine its effectiveness in managing these allergic conditions. The study will also gather data on various health measures, including levels of specific antibodies in the blood, to better understand the vaccine’s impact on the immune system.
Spain 
